// App-Quantinova.ai

5037 : Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Fred Saad

Principal Investigators

  • Gerhardt Attard

  • Thomas W. Flaig

  • Fabio Franke

  • Oscar Goodman

  • Stephane Oudard

  • Thomas Steuber

  • Hiroyoshi Suzuki

  • Christopher Michael Pieczonka

  • Francis Parnis

  • Daphne Wu

  • Kesav Yeruva

  • Peter De Porre

  • Sabine Doris Brookman-May

  • Susan Li

  • Jinhui Li

  • Suneel Mundle

  • Sharon Anne McCarthy

  • Dana E. Rathkopf

Medical Centers

  • Centre Hospitalier de l'Université de Montréal, Montreal

  • Canada.

  • Athens Medical Center, Athens, TX

  • Greece

  • Kings College London, London, United Kingdom

  • University of Colorado Cancer Center, Aurora, CO

  • Oncosite/Hospital Unimed Noroeste, Ijuí, Brazil

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Georges Pompidou Hospital, University René Descartes, Paris, France

  • Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Toho University Sakura Medical C, Kashiwa-City, Japan

  • Associated Medical Professionals of NY, PLLC, Syracuse, NY

  • Ashford Cancer Centre Research, Adelaide, SA, Australia

  • Janssen Research & Development, Los Angeles, CA

  • Janssen Research & Development, Beerse, Belgium

  • Ludwig Maximilians University Munich, Munich, Germany

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research & Development, San Diego, CA

  • Janssen Research & Development, LLC, Raritan, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Canada

  • United States

  • Greece

  • United Kingdom

  • Brazil

  • France

  • Germany

  • Japan

  • Australia

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Prednisone

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • N/A

Study Id's

  • NCT02257736

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved